Characterizing the role of AMPK in human T cells during GVHD, as well as the impact of its deficiency on T cell responses and disease pathogenesis, will be necessary to validate the feasibility of targeting AMPK to mitigate GVHD clinically. This evidence concerns the gene PRKAA1 and graft versus host disease.